Overview

To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants

Status:
RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effects of nirogacestat 100 mg twice daily (BID) on the pharmacokinetics (PK) of a cytochrome P450 (CYP) cocktail.
Phase:
PHASE1
Details
Lead Sponsor:
SpringWorks Therapeutics, Inc.
Treatments:
nirogacestat